Lv11
90 积分 2025-02-06 加入
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages
4小时前
已完结
JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat
4小时前
已完结
nemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis
12天前
已完结
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors
19天前
已完结
A spotlight on using HIF-PH inhibitors in renal anemia
19天前
已完结
Prevalence of Chronic Kidney Disease in China
20天前
已完结
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
20天前
已完结
Mechanisms of Anemia in CKD
20天前
已完结
Clinically Approved Small-Molecule Drugs for Anemia Therapy
25天前
已关闭
Prevalence and Disease Burden of Chronic Kidney Disease
26天前
已完结
皖公网安备34019202002308
